Journal
VACCINE
Volume 23, Issue 50, Pages 5768-5774Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2005.07.049
Keywords
immunotherapy; HPV; VSSP
Categories
Ask authors/readers for more resources
Peptide-based vaccines aimed at the induction of effective T-cell responses against established tumors have not been successful in clinic and require the use of new adjuvants. One of those is a new adjuvant in which gangliosides are incorporated into the outer membrane protein complex of Neisseria meningitidis to form very small size proteoliposomes (VSSP). In a preclinical model of human papillomavirus HPV 16-induced cervical cancer we show that vaccination with HPV 16 E7 derived minimal CTL peptide and VSSP protects mice against tumor challenge, induces regression of established tumors and produces E7-specific CD8(+) T-cell responses. (c) 2005 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available